Cover Image
市場調查報告書

Celladon Corporation:產品平台分析

Celladon Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 321948
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Celladon Corporation:產品平台分析 Celladon Corporation - Product Pipeline Review - 2014
出版日期: 2014年12月31日 內容資訊: 英文 27 Pages
簡介

Celladon Corporation是活用分子心臟學領域的新技能來發現循環系統治療上的劃時代分子治療法,並將之開發、製造、商品化的生物科技企業。

本報告提供Celladon Corporation 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,同時也提供最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Celladon Corporation 基本資料

Celladon Corporation 概要

  • 主要資訊
  • 企業資料

Celladon Corporation:R&D 概要

  • 主要的治療範圍

Celladon Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Celladon Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Celladon Corporation:藥物簡介

  • Mydicar
  • Gene therapy to Activate mSCF for Ischemic Cardiomyopathy
  • Small Molecule Modulators of SERCA2b for Metabolic and Neurodegenerative Disorders

Celladon Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Celladon Corporation:最近的開發平台趨勢

Celladon Corporation:暫停中的計劃

Celladon Corporation:總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC06766CDB

Summary

Global Markets Direct's, 'Celladon Corporation - Product Pipeline Review - 2014', provides an overview of the Celladon Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celladon Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Celladon Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Celladon Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Celladon Corporation's pipeline products

Reasons to buy

  • Evaluate Celladon Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Celladon Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Celladon Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Celladon Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celladon Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Celladon Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celladon Corporation Snapshot
    • Celladon Corporation Overview
    • Key Information
    • Key Facts
  • Celladon Corporation- Research and Development Overview
    • Key Therapeutic Areas
  • Celladon Corporation- Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products- Monotherapy
  • Celladon Corporation- Pipeline Products Glance
    • Celladon Corporation- Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Celladon Corporation- Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Celladon Corporation- Drug Profiles
    • Mydicar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene therapy to Activate mSCF for Ischemic Cardiomyopathy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule Modulators of SERCA2b for Metabolic and Neurodegenerative Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celladon Corporation- Pipeline Analysis
    • Celladon Corporation- Pipeline Products by Target
    • Celladon Corporation- Pipeline Products by Route of Administration
    • Celladon Corporation- Pipeline Products by Molecule Type
    • Celladon Corporation- Pipeline Products by Mechanism of Action
  • Celladon Corporation- Recent Pipeline Updates
  • Celladon Corporation- Dormant Projects
  • Celladon Corporation- Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celladon Corporation, Key Information
  • Celladon Corporation, Key Facts
  • Celladon Corporation- Pipeline by Indication, 2014
  • Celladon Corporation- Pipeline by Stage of Development, 2014
  • Celladon Corporation- Monotherapy Products in Pipeline, 2014
  • Celladon Corporation- Phase II, 2014
  • Celladon Corporation- Preclinical, 2014
  • Celladon Corporation- Pipeline by Target, 2014
  • Celladon Corporation- Pipeline by Route of Administration, 2014
  • Celladon Corporation- Pipeline by Molecule Type, 2014
  • Celladon Corporation- Pipeline Products by Mechanism of Action, 2014
  • Celladon Corporation- Recent Pipeline Updates, 2014
  • Celladon Corporation- Dormant Developmental Projects,2014

List of Figures

  • Celladon Corporation - Pipeline by Top 10 Indication, 2014
  • Celladon Corporation - Pipeline by Stage of Development, 2014
  • Celladon Corporation - Monotherapy Products in Pipeline, 2014
  • Celladon Corporation - Pipeline by Top 10 Target, 2014
  • Celladon Corporation - Pipeline by Top 10 Route of Administration, 2014
  • Celladon Corporation - Pipeline by Top 10 Molecule Type, 2014
  • Celladon Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top